[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Humacyte Inc (HUMA)

Humacyte Inc (HUMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 235,340
  • Shares Outstanding, K 222,019
  • Annual Sales, $ 2,040 K
  • Annual Income, $ -40,830 K
  • EBIT $ -108 M
  • EBITDA $ -101 M
  • 60-Month Beta 2.31
  • Price/Sales 117.65
  • Price/Cash Flow N/A
  • Price/Book 67.04

Options Overview Details

View History
  • Implied Volatility 155.34% (+25.42%)
  • Historical Volatility 108.61%
  • IV Percentile 73%
  • IV Rank 24.06%
  • IV High 366.53% on 03/09/26
  • IV Low 88.42% on 07/03/25
  • Expected Move (DTE 5) 0.1785 (16.84%)
  • Put/Call Vol Ratio 1.89
  • Today's Volume 4,382
  • Volume Avg (30-Day) 979
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 85,652
  • Open Int (30-Day) 82,758
  • Expected Range 0.8815 to 1.2385

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.10
  • Number of Estimates 1
  • High Estimate $-0.10
  • Low Estimate $-0.10
  • Prior Year $-0.10
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6031 +75.76%
on 04/10/26
1.0900 -2.75%
on 05/08/26
+0.4085 (+62.70%)
since 04/08/26
3-Month
0.5469 +93.82%
on 03/30/26
1.3100 -19.08%
on 03/10/26
+0.1217 (+12.97%)
since 02/06/26
52-Week
0.5469 +93.82%
on 03/30/26
2.9300 -63.82%
on 06/06/25
-0.1500 (-12.40%)
since 05/08/25

Most Recent Stories

More News
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti , LLC (“KSF”), announces that KSF has commenced an investigation into...

HUMA : 1.0600 (-1.85%)
Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026

DURHAM, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial...

HUMA : 1.0600 (-1.85%)
Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

DURHAM, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial...

HUMA : 1.0600 (-1.85%)
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

NEW YORK and NEW ORLEANS , April 24, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti , LLC ("KSF"), announces...

HUMA : 1.0600 (-1.85%)
Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®

- Ex-U.S. rights realigned under amendment to distribution agreement with Fresenius Medical Care -  - Positions Humacyte to advance discussions with corporate partners regarding international and...

HUMA : 1.0600 (-1.85%)
Humacyte Appoints Jim Mercadante as Chief Commercial Officer

– Industry veteran with more than 25 years of experience will lead next phase of biotech company’s commercial expansion – – Seasoned medtech commercial leader brings extensive field-specific...

HUMA : 1.0600 (-1.85%)
Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair

- The Ministry of Health has set a 180-working-day review period for the MAA -  - MAA process is one step in planned expansion of Symvess into multiple countries outside of the U.S - DURHAM,...

HUMA : 1.0600 (-1.85%)
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti , LLC (“KSF”), announces that KSF has commenced an investigation into...

HUMA : 1.0600 (-1.85%)
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...

HUMA : 1.0600 (-1.85%)
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year -  - Purchase commitment received for a minimum of $1.475 million for...

HUMA : 1.0600 (-1.85%)

Business Summary

Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C.

See More

Key Turning Points

3rd Resistance Point 1.1767
2nd Resistance Point 1.1333
1st Resistance Point 1.0967
Last Price 1.0600
1st Support Level 1.0167
2nd Support Level 0.9733
3rd Support Level 0.9367

See More

52-Week High 2.9300
Fibonacci 61.8% 2.0197
Fibonacci 50% 1.7385
Fibonacci 38.2% 1.4572
Last Price 1.0600
52-Week Low 0.5469

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.